Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jun;11(6):509-14.
doi: 10.1007/BF01960805.

Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients

Affiliations
Clinical Trial

Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients

S M Kelsey et al. Eur J Clin Microbiol Infect Dis. 1992 Jun.

Erratum in

  • Eur J Clin Microbiol Infect Dis 1992 Oct;11(10):960

Abstract

Teicoplanin plus ciprofloxacin was compared with gentamicin plus piperacillin for the empirical treatment of fever in 80 neutropenic patients. A favourable response was seen in 78% of patients receiving teicoplanin plus ciprofloxacin and in 49% receiving gentamicin plus piperacillin (p less than 0.05). When microbiologically documented episodes were analysed separately, the response to teicoplanin plus ciprofloxacin was favourable in 81% of patients whereas only 35% responded favourably to gentamicin plus piperacillin (p = 0.034). Gram-positive organisms accounted for 76% of bacterial isolates, Staphylococcus epidermidis being the most common pathogen. Ten of 12 (83%) Staphylococcus epidermidis infections resolved when treated with teicoplanin plus ciprofloxacin as compared with 2 of 8 (25%) treated with gentamicin plus piperacillin. Teicoplanin is at least as effective as gentamicin plus piperacillin in the empirical treatment of febrile neutropenic patients and may be more effective in situations where gram-positive organisms are prevalent. The high incidence of gram-positive infections in our unit justifies the use of an agent with specific activity against gram-positive organisms in the first-line antibiotic regimen.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Antimicrob Agents Chemother. 1987 Jul;31(7):971-7 - PubMed
    1. J Infect Dis. 1991 May;163(5):951-8 - PubMed
    1. J Infect Dis. 1990 Mar;161(3):397-401 - PubMed
    1. Ann Intern Med. 1982 Oct;97(4):503-8 - PubMed
    1. J Antimicrob Chemother. 1988 Aug;22(2):237-47 - PubMed

Publication types

MeSH terms

LinkOut - more resources